Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?

Although imatinib is a standard treatment for metastatic or recurrent gastrointestinal stromal tumors (GISTs), acquired c-kit mutations reportedly cause secondary resistance to imatinib. Sunitinib is a tyrosine kinase inhibitor (TKI) that can be used as second-line therapy in imatinib-resistant or -...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Gastroenterol Hepatol
Autors principals: Kikuchi, Hirotoshi, Hiramatsu, Yoshihiro, Kamiya, Kinji, Morita, Yoshifumi, Sakaguchi, Takanori, Konno, Hiroyuki, Takeuchi, Hiroya
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2018
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5897690/
https://ncbi.nlm.nih.gov/pubmed/29682621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tgh.2018.02.02
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars